Macular vitelliform lesion in desferrioxamine-related retinopathy

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Documenta Ophthalmologica

• Publication date

  2010-06-09

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s10633-010-9236-zPMID 20532952PMCID PMC3690284
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• ISCEV Standard for full-field clinical electroretinography (2008 update)

  2009cited by this paper
• [Retinal pigment epithelium--desferal].

  2007cited by this paper
• Bilateral vitelliform maculopathy and deferoxamine toxicity.

  2004influential reference
• Standard for clinical electroretinography (2004 update)

  2004cited by this paper
• Bull's eye maculopathy with deferoxamine

  2003cited by this paper
• Iron chelators for the treatment of iron overload disease: Relationship between structure, redox activity, and toxicity

  2003cited by this paper
• The expanded clinical spectrum of deferoxamine retinopathy.

  2002cited by this paper
• Rod and rod mediated function in patients with β-thalassemia major

  1998cited by this paper
• Rod and rod mediated function in patients with beta-thalassemia major.

  1998cited by this paper
• A Risk-Benefit Assessment of Iron-Chelation Therapy

  1997cited by this paper
• Deferoxamine-associated retinopathy after subcutaneous injection.

  1994cited by this paper
• Vision and hearing during deferoxamine therapy.

  1990cited by this paper
• Ocular and auditory toxicity in hemodialyzed patients receiving desferrioxamine.

  1990cited by this paper
• Irreversible ocular toxicity from single "challenge" dose of deferoxamine.

  1989cited by this paper
• Ocular toxicity of desferrioxamine--an example of copper promoted auto-oxidative damage?

  1989cited by this paper
• Depletion of trace elements and acute ocular toxicity induced by desferrioxamine in patients with thalassaemia.

  1988cited by this paper
• Ocular and auditory toxicity of long-term, high-dose subcutaneous deferoxamine therapy.

  1985cited by this paper
• Deferoxamine (Desferal)-induced toxic retinal pigmentary degeneration and presumed optic neuropathy.

  1984cited by this paper
• Ocular changes in patients undergoing long-term desferrioxamine treatment.

  1984cited by this paper
• Ocular toxicity of high-dose intravenous desferrioxamine.

  1983cited by this paper
• BROMOCRIPTINE AND SERUM-GROWTHHORMONE LEVELS IN DIABETES MELLITUS

  1975cited by this paper

• [Deferoxamine maculopathy].

  2025cites this paper
• Effects of medications on hypoxia‐inducible factor in the retina: A review

  2023cites this paper
• Multimodal imaging of desferoxamine retinopathy

  2023cites this paper
• The Impact of Systemic Medications on Retinal Function.

  2023cites this paper
• Vitelliform maculopathy: Diverse etiologies originating from one common pathway.

  2023cites this paper
• Long-Term Effects of Iron Chelating Agents on Ocular Function in Patients with Thalassemia Major

  2021cites this paper
• Long-Term Effects of Iron Chelating Agents on Ocular Function in Patients with Thalassemia Major

  2021cites this paper
• Desferrioxamine-Related Pseudo-Vitelliform Dystrophy and the Effect of Anti-Vascular Endothelial Growth Factor

  2021cites this paper
• Vitelliform changes in the central retina occurring in adults

  2020cites this paper
• Ocular abnormalities in beta thalassemia patients: prevalence, impact, and management strategies

  2019cites this paper
• Pattern dystrophies in patients treated with deferoxamine: report of two cases and review of the literature

  2018cites this paper
• Pseudovitelliform maculopathy associated with deferoxamine toxicity: multimodal imaging and electrophysiology of a rare entity.

  2017cites this paper
• Iron chelation for the treatment of uveitis.

  2017cites this paper
• Electrophysiological assessment for early detection of retinal dysfunction in β-thalassemia major patients

  2017cites this paper
• The Pattern Dystrophies

  2016cites this paper
• β-Thalassemia and ocular implications: a systematic review

  2016cites this paper
• Retinal abnormalities in β-thalassemia major.

  2016cites this paper
• Clinical applications of fundus autofluorescence in retinal disease

  2016cites this paper
• Functional and Structural Abnormalities in Deferoxamine Retinopathy: A Review of the Literature

  2015cites this paper
• Adult-onset foveomacular vitelliform dystrophy: A fresh perspective.

  2015cites this paper
• Multimodal imaging in a case of deferoxamine-induced maculopathy.

  2014cites this paper
• The spectrum of ocular alterations in patients with β-thalassemia syndromes suggests a pathology similar to pseudoxanthoma elasticum.

  2014cites this paper
• MULTIMODAL IMAGING IN DEFEROXAMINE RETINOPATHY

  2014cites this paper
• Deferoxamine retinopathy: spectral domain-optical coherence tomography findings

  2014cites this paper
• Spectral domain optical coherence tomography findings in early deferoxamine maculopathy: report of two cases.

  2014cites this paper
• Efficacy of brinzolamide ophthalmic suspension 1% for treatment of a vitelliform macular lesion in a patient with desferrioxamine retinopathy.

  2011cites this paper